Skip to main content
All lobbying clients

NOVOCURE INC.

Lobbying client · New Hampshire · filed 2025 to 2026

Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.

$180,000 Reported spend
4 Filings counted
1 Firms hired
2 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page is grouped by the client's LDA id (69890), not by name.

 Firms hired 1
 Bills named in these filings 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
    4 filings
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
    4 filings
 Reported by year 2 years
  • 2026 $120,000 2 filings
  • 2025 $60,000 2 filings
 Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 2
  • HOUSE OF REPRESENTATIVES 3
  • SENATE 3
 Foreign entities disclosed 3
  • NOVOCURE GMBH Switzerland named on 4 filings · highest disclosed ownership 100% · largest disclosed contribution $0
  • NOVOCURE LUXEMBOURG S.A.R.L. (OWNS 100% OF NOVOCURE GMBH) Luxembourg named on 4 filings · highest disclosed ownership 100% · largest disclosed contribution $0
  • NOVOCURE LIMITED (OWNS 100% OF NOVOCURE LUXEMBOURG) Jersey named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem